

RECEIVED  
CENTRAL FAX CENTER  
SEP 28 2006

## IN THE CLAIMS

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims

Claim 1 (Currently amended): A replication-competent adenovirus vector comprising ~~[[an]]~~ a first adenovirus gene essential for replication under transcriptional control of an Epstein Barr Virus (EBV)-specific transcriptional regulatory element (TRE) comprising a sequence selected from the group consisting of a sequence upstream of the translational start codon for the LMP1 gene presented as SEQ ID NO:1, a sequence upstream of the translational start codon for the LMP2A gene presented as SEQ ID NO:2 and the Cp promoter sequence presented as SEQ ID NO:3.

Claim 2 (Currently amended): The adenovirus vector according to Claim 1, wherein said EBV-specific TRE comprises a sequence ~~derived from the sequence~~ 5' to the translational start codon for the LMP1 EBV gene (SEQ ID NO:1).

Claim 3 (original): The adenovirus vector according to Claim 2, wherein said EBV-specific TRE comprises the sequence set forth in SEQ ID NO:1.

Claim 4 (Currently amended): The adenovirus vector according to Claim 3, wherein said EBV-specific TRE comprises the ED-L1 regulatory region of SEQ ID NO:1.

Claim 5 (Currently amended): The adenovirus vector according to Claim 3, wherein said EBV-specific TRE comprises the L1-TR regulatory region of SEQ ID NO:1.

Claim 6 (Currently amended): The adenovirus vector according to Claim 1, wherein said EBV-specific TRE comprises a sequence ~~derived from the sequence~~ 5' to the translational start codon for the LMP2A EBV gene (SEQ ID NO:2).

Claim 7 (original): The adenovirus vector according to Claim 6, wherein said EBV-specific TRE comprises the sequence set forth in SEQ ID NO:2.

Claim 8 (Currently amended): The adenovirus vector according to Claim 1, wherein said EBV-specific TRE ~~further comprises a human~~ the Cp promoter set forth in SEQ ID NO:3 or ~~enhancer.~~

Claim 9 (Currently amended): The adenovirus vector according to Claim ~~[[1]]~~8, wherein said EBV-specific TRE further comprises ~~a human transcriptional regulatory factor response element~~ the FR enhancer set forth in SEQ ID NO:4.

Claim 10 (Currently amended): The adenovirus vector according to Claim 1, wherein said EBV-specific TRE further ~~comprises a promoter and~~ the FR enhancer set forth in SEQ ID NO:4.

Claim 11 (cancelled)

Claim 12 (Currently amended): The adenovirus vector according to Claim 1, ~~wherein the adenoviral vector comprises first and~~ further comprising a second adenoviral genes co- transcribed under transcriptional control of said EBV-specific TRE.

Claim 13 (original): The adenovirus vector according to Claim 12, wherein the second adenoviral gene is under translational control of an IRES.

Claim 14 (original): The adenovirus vector of Claim 1, wherein said adenoviral gene essential for replication is E1A or E1B.

Claim 15 (original): The adenovirus vector of Claim 14, wherein E1A or E1B has a mutation in, or deletion of, its endogenous promoter.

Claim 16 (original): The adenovirus vector of Claim 15, wherein E1B has a deletion of the 19-kDa region.

Claim 17 (original): A composition comprising:  
a replication-competent adenovirus vector according to Claim 1 and a pharmaceutically acceptable excipient.

Claim 18 (Currently amended): An isolated host cell comprising the adenovirus vector of claim 1.

Claim 19 (New): A composition comprising:  
a replication-competent adenovirus vector according to Claim 10 and a pharmaceutically acceptable excipient.

Claim 20 (New): An isolated host cell comprising the adenovirus vector of Claim 10.